Navigation Links
Gleevec, the targeted cancer pill, delivers more good news to patients
Date:12/9/2007

PORTLAND, Ore. Gleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia.

Data at this weekends meeting continues to show how much Gleevec has completely changed the outlook for so many, many patients facing cancer, said Brian Druker, M.D., director of the OHSU Cancer Institute.

At the plenary session of the annual meeting of the American Society of Hematology researchers delivered news that Gleevec has been shown to improve outcomes for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Ph+ ALL is the childhood leukemia with the worst prognosis and the Childrens Oncology Group study shows that adding Gleevec to the treatment almost completely reverses this poor prognosis. The Childrens Oncology Group is a worldwide clinical trial cooperative supported by the National Cancer Institute, a branch of the National Institutes of Health.

Also released at the conference is new data from the largest clinical trial in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that showed Gleevec, with long-term use, can prevent progression to advanced stages of the disease.

Six-year results of the International Randomized Interferon versus STI571 (IRIS) study for which Druker served as principal investigator, demonstrated that continuous treatment with Gleevec produced a declining rate of relapse over time. The downward trend in the risk of disease progression while on Gleevec has continued since year two of the study. Remarkably, between years five and six, no patients progressed to an advanced phase of the disease.

The news about Gleevec and the childhood leukemia study as well as the six-year IRIS study that shows there is no progression to advanced phase in CML means that more and more patients
'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study suggests brain tumors need treatment with multiple targeted drugs
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Research suggests targeted treatment strategies for lupus
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
6. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
7. Survival differences by race most apparent in advanced stages of breast cancer
8. MRI finds breast cancer before it becomes dangerous
9. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
10. Pathway links inflammation, angiogenesis and breast cancer
11. Radiologists encouraged to look beyond cancer for clinically unseen diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Florida (PRWEB) November 21, 2014 Nature’s Sleep is ... Sleep contest . The contest calls for the creation of any ... a photo — that encompasses sleep, a bed or a mattress. ... year,” said Alan Hirschhorn, Vice President of Marketing for Nature’s Sleep, ... an array of more than 10,000 creative entries from some very ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, 2014 ... of a still-beating heart has the potential to improve the ... new study. Heart patients who received the gel implant ... hundreds of feet farther during a six-minute walk test, said ... cardiovascular division at Washington University School of Medicine and a ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. ... excess or binge drink are not alcoholics, a new U.S. ... who drink too much aren,t dependent on alcohol. But one ... Centers for Disease Control and Prevention. , , "A lot of ... alcoholics," said study co-author Dr. Robert Brewer, the leader of ...
(Date:11/18/2014)... November 18, 2014 Cristcot Inc., ... development and commercialization of specialized drug delivery systems, ... granted Cristcot a patent for the technology, which ... Sephure®. , The patent was awarded to ... rights have been assigned to Cristcot Inc. The ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, ... cholesterol down to extremely low levels with a combination ... in high-risk patients with clogged arteries, a new study ... when taking Vytorin, a drug that combines a cholesterol-lowering ... said principal investigator Dr. Christopher Cannon, a cardiologist at ...
Breaking Medicine News(10 mins):Health News:Nature’s Sleep Kicks Off their 2nd Art Of Sleep Contest 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 2Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 3Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3
... HARRISBURG, Pa. , Sept. 8 ... for subsidized health insurance coverage, state Insurance Commissioner Joel Ario today urged ... that will give Pennsylvania and other states tools needed to fix the ... , "Lost in the din of the recent town hall ...
... Delta Health , an InfoLogix, ... that it has been selected by Hennepin County Medical Center in ... impact margins through productivity management. , , (Logo: ... , Delta Health has helped hospitals across North America ...
... , NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... that it has filed a patent for a novel ... thus has blockbuster potential as a new anti-cancer drug. ... which is highly reactive to prostate cancer cells, and ...
... Sept. 8 MRSA Survivors Network, the Chicago-based nonprofit and official ... lift the veil of secrecy surrounding MRSA. The history making ... October 1st. The 2009 theme is "You Can Not Change What ... http://www.newscom.com/cgi-bin/prnh/20090825/DC65136LOGO ) , , Founder ...
... , NEW YORK, Sept. 8 NeoStem, ... pioneering the pre-disease collection, processing and long-term storage of adult stem ... Robin Smith, M.D., MBA, will present on the Company,s latest strategic ... New York Palace Hotel in New York City on September 9-11, ...
... , , WALTHAM, Mass., ... the global authority on medical technology market intelligence, the ... experience considerable growth in sales over the next five ... 2009 report finds, however, that product safety issues ...
Cached Medicine News:Health News:Insurance Commissioner Says Federal Health Care Reform Necessary to Fix a Broken System 2Health News:Delta Health, an InfoLogix Company, Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 2Health News:Delta Health, an InfoLogix Company, Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 3Health News:Genova files patent for new prostate cancer treatment 2Health News:MRSA Activists to Lift the Veil of Secrecy on World MRSA Day 2Health News:NeoStem to Present at Rodman & Renshaw's 11th Annual Healthcare Conference 2Health News:NeoStem to Present at Rodman & Renshaw's 11th Annual Healthcare Conference 3Health News:Will the FDA Ban Hydroquinone in Pigment Control Products? 2Health News:Will the FDA Ban Hydroquinone in Pigment Control Products? 3
(Date:11/21/2014)... , Nov. 20, 2014   Wellcentive , ... (PHM) for healthcare organizations, announced today being named ... 2014 Intel Innovation Award .  Sponsored by Intel, ... in its fourth year, recognizes companies developing leading-edge ... healthcare delivery processes. Wellcentive,s ...
(Date:11/21/2014)... Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... its offering of $80,000,000 aggregate principal amount of 5.25% ... a private offering within the United States ... institutional buyers pursuant to Rule 144A under the Securities ... has also granted the initial purchasers an option to ...
(Date:11/18/2014)... WALTHAM, Mass. , Nov. 18, 2014 ... one of the leading medical device and services providers ... Motion,s exclusive partner for Respiratory Motion,s innovative respiratory depression ... Respiratory Motion and IMI are working together to connect ... IMI has a long history of bringing innovative medical ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
... Pharmaceuticals Inc . (Nasdaq: CPIX) is pleased to ... Directors. A healthcare veteran with more than 30 ... President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. ... $2 billion behavioral healthcare system before the company,s sale to ...
... Jan. 6, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: ... China, announced today its preliminary unaudited sales range for the ... conference call to discuss these preliminary sales will be held ... (January 6, 2011 at 9:00 pm China Standard Time). The ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors 2Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range 2Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range 3
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
... people are diagnosed with varicose veins every ... never seek treament and are apprehensive of ... them an effective alternative to conventional therapies., ... hook phlebectomy), is considered a laborious procedure ...
Inquire...
...
Medicine Products: